About cytek biosciences inc - CTKB
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.
CTKB At a Glance
Cytek Biosciences, Inc.
47215 Lakeview Boulevard
Fremont, California 94538
| Phone | 1-877-922-9835 | Revenue | 201.49M | |
| Industry | Medical Specialties | Net Income | -66,539,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 0.519% | |
| Fiscal Year-end | 12 / 2026 | Employees | 700 | |
| View SEC Filings |
CTKB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.202 |
| Price to Book Ratio | 1.90 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.665 |
| Enterprise Value to Sales | 2.068 |
| Total Debt to Enterprise Value | 0.079 |
CTKB Efficiency
| Revenue/Employee | 287,847.143 |
| Income Per Employee | -95,055.714 |
| Receivables Turnover | 2.794 |
| Total Asset Turnover | 0.418 |
CTKB Liquidity
| Current Ratio | 5.038 |
| Quick Ratio | 4.416 |
| Cash Ratio | 3.361 |
CTKB Profitability
| Gross Margin | 51.843 |
| Operating Margin | -20.042 |
| Pretax Margin | -14.81 |
| Net Margin | -33.023 |
| Return on Assets | -13.81 |
| Return on Equity | -18.045 |
| Return on Total Capital | -17.755 |
| Return on Invested Capital | -17.139 |
CTKB Capital Structure
| Total Debt to Total Equity | 9.664 |
| Total Debt to Total Capital | 8.812 |
| Total Debt to Total Assets | 7.155 |
| Long-Term Debt to Equity | 6.248 |
| Long-Term Debt to Total Capital | 5.698 |